Background {#s1}
==========

Medicines optimization aims to ensure that patients get the most from their medicines.^[@LDU021C1]^ Although beneficial and relatively uncontroversial, it is difficult to achieve in practice given the multiple stages in the medicines pathway (prescribing, dispensing, administration, monitoring and record keeping) and complex interactions between the different stakeholders (e.g. clinicians, pharmacists, patients, etc.). As a result, only a proportion of patients get the maximum benefit from their medicines and some suffer avoidable harm. Suboptimal use of medicines can also result in extra costs for healthcare systems, such as in hospitalizations related to prescribing or monitoring errors, or morbidity from low patient adherence. Therefore, addressing suboptimal use of medicines is likely to achieve better health outcomes and to ensure a more efficient use of resources.

The benefits of improving suboptimal use of medicines have long been recognized, both in the UK and internationally.^[@LDU021C1],[@LDU021C2]^ The UK National Health Service (NHS), in particular, has deployed a number of initiatives to address the issue. The National Prescribing Centre, part of the National Institute for Health and Care Excellence (NICE) since 2011, was established in the late 1990s to support the NHS in improving prescribing and medicine use. NICE has had a large role in improving medicines use by issuing guidance on the effectiveness and cost-effectiveness of new medicines and guidelines on good practice, specifically around medicines reconciliation and discharge and adherence to medicines.^[@LDU021C3],[@LDU021C4]^ Nonetheless, medicines optimization remains an elusive goal and more needs to be done to improve medicines use.

The challenge is to identify how best to intervene given the differences in effectiveness and cost-effectiveness of potential interventions that could be invested on by the NHS. In other words, which interventions are more likely to deliver the best health outcomes (and/or lower costs)? However, suboptimal use of medicines covers a large number of issues, each specific to different stages in the medicines pathway. Comparing the effectiveness and cost-effectiveness of all possible interventions related to suboptimal use of medicines would be impossible. Therefore, the first step is to gain an understanding of the size and the nature of the evidence base in order to highlight the areas with the largest body of research and areas where new research may be required. As such, a scoping review was conducted on the effectiveness and cost-effectiveness of interventions to address suboptimal use of medicines. Rather than addressing specific research questions on, for example, the comparative effectiveness of interventions, a scoping review seeks to identify gaps in the existing literature to inform where more research may be needed.^[@LDU021C5]^ Hence, this review is a ground-clearing exercise that maps out the evidence base on how to improve suboptimal use of medicines and pinpoints where future research would have the most value. The results of this scoping review can be used as a starting point for a systematic review on specific interventions to improve suboptimal use of medicines or as supportive evidence for future primary research.

Methods {#s2}
=======

Typology of issues affecting the medicines pathway {#s2a}
--------------------------------------------------

Figure [1](#LDU021F1){ref-type="fig"} describes the medicines pathway and presents a typology of issues considered throughout this review. The medicines pathway can be seen as a cycle starting at prescribing. Prescribing can be performed by a number of healthcare professionals, including doctors, dentists, nurses, pharmacists, optometrists, etc. depending on their qualifications and the medicines considered. Prescribing is a complex act as it requires consideration of the diagnosis, the response to previous medicines prescribed to treat the problem, guidelines on the condition, and the preferences and characteristics of the patient. Therefore, it can be affected by a number of issues, namely lack of compliance with guidelines, inappropriate prescribing given the patients\' characteristics, prescribing errors or insufficient prescribing of low-cost generics. Prescriptions are dispensed in the pharmacy. Dispensing errors can occur at the point of supply, with varying degrees of severity; conversely, prior prescribing errors can be detected and addressed during dispensing. Administration can be by the patient himself or herself or by a carer (informal or formal carer). Two issues can occur at the administration stage: errors (e.g. too much or too little by mistake) and non-adherence. Non-adherence is a complex and important issue. It can be non-intentional (e.g. due to not understanding administration instructions or forgetfulness) or intentional, whereby the patient consciously decides not to take the medicine. Medicines often require patient monitoring, for efficacy and adverse events, sometimes involving laboratory measurement of their effect (e.g. international normalized ratio for warfarin). Information regarding prescribing, dispensing, monitoring and, in some sectors, administration (such as care homes or in hospital) should be appropriately recorded to inform the subsequent stages in the cycle in what is termed as 'record keeping'. Fig. 1Issues around suboptimal use of medicines.

A number of issues emerge from the stages and complex interactions between stakeholders along the medicines pathway: lack of compliance with guidelines, inappropriate prescribing (including under- or over-prescribing), prescribing errors, insufficient prescribing of generics, dispensing errors, non-adherence, monitoring errors and issues specific to the interface between care sectors in medicines reconciliation and discharge and around medicines management in care homes. This list of issues is not exhaustive but can guide the categorization of the evidence base into topics of research. They were chosen based on rapid review of the literature on the burden of suboptimal use of medicines and discussions with expert researchers in the area and policy advisors (see Acknowledgements for the list of advisors consulted for this study).^[@LDU021C6]^

Data sources and searches {#s2b}
-------------------------

Searches were conducted in three databases: the NHS Economic Evaluation Database (NHS EED) for cost-effectiveness studies and the Cochrane Database of Systematic Reviews and the Database of Abstracts of Reviews of Effects (DARE) for systematic reviews. NHS EED contains cost-effectiveness studies of healthcare interventions and is updated weekly. Included studies are published in the database and prioritized for abstract writing. Structured abstracts are written and independently checked by health economists. DARE contains systematic reviews of the effects of healthcare interventions and the delivery and organization of health services and is updated weekly; citations identified as potential systematic reviews are assessed for inclusion by two researchers. Reviews need to meet at least four of five criteria (criteria 1--3 are mandatory) to be included: (1) inclusion/exclusion criteria are reported; (2) adequate search; (3) included studies are synthesized; (4) quality of the studies is assessed; (5) there are sufficient details about the included studies. Reviews are then published in the database and prioritized for abstract writing. Structured abstracts are written by researchers and checked by a technical editor. DARE includes records of all Cochrane reviews and protocols, as well as published papers associated with Cochrane reviews. More details on these databases can be found here <http://www.crd.york.ac.uk/CRDWeb/AboutPage.asp> (5 August 2014, date last accessed).

The bibliographic search strategies were designed to provide an overview of the literature and to identify any evidence gaps. The strategies were designed by an information specialist in consultation with the researchers. A combination of relevant free text terms, synonyms and subject headings were included. The process was iterative; sample sets of results were screened for relevance and a reasonable level of inclusivity and the findings from this were used to fine tune the strategy. The base search strategy was constructed using the Cochrane Library and then adapted to the other resources searched. The evidence base around effectiveness was assessed from systematic reviews since there was an expectation of a large body of literature in the area. Grey literature (work published in channels other than peer-reviewed journals) was not examined since the objective is to map out the size and the nature of the evidence base rather than an exhaustive review of all the evidence. Searches were conducted in February 2013 and were limited to material published since 2000 written in English. The date limit was applied to increase the likelihood that the evidence identified is relevant to the current context and to the decision problems faced by policy-makers. Full details can be found in the [online supplementary data, Appendix](http://bmb.oxfordjournals.org/lookup/suppl/doi:10.1093/bmb/ldu021/-/DC1).

Study selection {#s2c}
---------------

Studies were selected following a stepwise procedure. First, articles with obviously irrelevant titles were excluded. Secondly, abstracts were retrieved, read and assessed based on three criteria: (i) whether the study assessed interventions related to medicines use, (ii) whether the study assessed the effectiveness or cost-effectiveness of interventions (as opposed to theory supporting their use, their development, procedures or experiences of the different stakeholders and (iii) whether the study was published in the English language. Thirdly, the structured abstract from NHS EED or DARE was retrieved, read and assessed to confirm inclusion. Cost-effectiveness studies were included only if two or more interventions were compared in terms of their costs and effects. Any measure of effect was considered, including quality of life, resource use, monetary values or other quantities of interest. Interventions to improve overall patients\' management in the whole pathway in a specific disease but which were not directly related to medicine use (e.g. asthma management) were excluded. Quality assessment was not conducted because it was outside the scope of this review.

Data extraction and synthesis {#s2d}
-----------------------------

Data were extracted from the NHS EED or DARE structured abstracts using a standardized form in Microsoft Excel. Full-text papers were consulted where the structured abstract was not available or if the abstract did not contain the information required. Data extraction included: objective, issue(s) of suboptimal use of medicines that interventions addressed as defined by the study\'s objective, type of study, type of intervention, target of the intervention and outcomes. The type of analysis (within trial or model based), the setting and the source of effectiveness data were extracted for cost-effectiveness studies. Extracting the relevant information from the structured abstracted, complemented as required by consulting the full text, was considered the most efficient and appropriate data extraction strategy given the aims of this review.

The studies were classified by the issue of suboptimal medicines use addressed, whether the evidence was generic or specific to a particular condition, the type of intervention and the type of outcome measures included. The classification of studies aimed to facilitate the identification of gaps in the literature and help define future research questions. Particular attention was given to data relevant to cost-effectiveness analysis (i.e. costs, health-related quality of life or quality-adjusted life years (QALYs)) in order to ascertain whether the existing evidence base is sufficient to draw conclusions on the value for money of interventions for the NHS. A narrative synthesis was undertaken.

Results {#s3}
=======

Figure [2](#LDU021F2){ref-type="fig"} presents the flowchart of the study selection process. Briefly, 646 records were found, of which 157 abstracts were assessed for eligibility. In total, 107 studies were included in the review (29 cost-effectiveness and 78 systematic reviews). Fig. 2PRISMA flow diagram of the study selection process.

Issues and interventions {#s3a}
------------------------

Table [1](#LDU021TB1){ref-type="table"} summarizes the disease areas and the type of intervention by issue of suboptimal use of medicines included in the 78 systematic reviews. The interventions were broadly classified based on their names and summary descriptions in one of the following categories: software support, pharmacist-led intervention, nurse-led intervention, multidisciplinary interventions (involving more than one healthcare professional), educational intervention (including interventions involving provision of information leaflets), counselling or behavioural intervention, financial incentives, aids or devices (such as adherence aids, reminders, including dose simplifications with the view of improving adherence), medicines review or reconciliation, protocols or guidelines. The objective was to obtain a manageable number of types of interventions whilst maintaining some detail to assess on which areas was the evidence base more or less prominent. Every one of the issues around suboptimal medicines use was addressed by the systematic reviews with the exception of insufficient prescribing of generics. Most studies evaluated more than one type of intervention as the systematic reviews were typically on any intervention to improve a specific issue related to suboptimal use of medicines. The majority of the studies (51, 65%) focussed on interventions to improve adherence either in any disease area (20; 39%) or for specific conditions (31; 69%). Interventions were mostly educational (35; 69%) such as leaflets or brochures,^[@LDU021C76]^ behavioural or counselling (24; 47%) such as group psychotherapy, cognitive behavioural therapy^[@LDU021C72]^ or family counselling therapy^[@LDU021C77]^ or involving adherence aids (19; 37%) such as unit-of-use packaging,^[@LDU021C33]^ reminders such as telephone reminders^[@LDU021C68]^ or dose simplifications.^[@LDU021C29]^ One review evaluated the effectiveness of incentives of the form of money, goods (such as bus tokens or food) or vouchers redeemable for goods to improve adherence to medications for tuberculosis, substance abuse, human immunodeficiency virus, hepatitis C, schizophrenia and stroke prevention.^[@LDU021C43]^ Prescription errors (10, 13%) were the second most frequent issue evaluated. All reviews relating to this issue included interventions involving software support such as computerized order entry,^[@LDU021C11],[@LDU021C20],[@LDU021C23]--[@LDU021C28]^ computerized reminders,^[@LDU021C22]^ automated bedside dispensing^[@LDU021C22]^ or computerized advice.^[@LDU021C21]^ Two reviews on prescription errors included a variety of interventions in addition to software support.^[@LDU021C22],[@LDU021C24]^ Table 1Disease area and type of studies included by issue of suboptimal medicines use in the systematic review (references in superscript numbers)Issue of suboptimal medicines use*N* (%)Disease areaType of interventionAllSpecific conditionsSoftware supportPharmacist -led InterventionNurse-led supportMultidisciplinary medicines managementEducation (inc. leaflets)Counselling or behavioural interventionFinancial incentivesAdherence aids, reminders, dose simplificationMedicines review or reconciliationProtocols or guidelinesLack of compliance with guidelines6 (8)^[@LDU021C7]--[@LDU021C11]^URTI^[@LDU021C12][@LDU021C7],\ [@LDU021C11],\ [@LDU021C12][@LDU021C8][@LDU021C9],\ [@LDU021C12][@LDU021C9],\ [@LDU021C10],\ [@LDU021C12][@LDU021C9][@LDU021C9][@LDU021C12]^Inappropriate prescribing (inc. antibiotics)9 (12)^[@LDU021C10],\ [@LDU021C11],\ [@LDU021C13]--[@LDU021C18]^Antibiotics^[@LDU021C19]11,\ 16--18[@LDU021C14][@LDU021C10],\ [@LDU021C15],\ [@LDU021C16],\ [@LDU021C19][@LDU021C13][@LDU021C14]^Prescription errors10 (13)^[@LDU021C11],\ [@LDU021C20]--[@LDU021C28][@LDU021C11],\ [@LDU021C20]--[@LDU021C28][@LDU021C22],\ [@LDU021C24][@LDU021C22][@LDU021C22],\ [@LDU021C24][@LDU021C22][@LDU021C24][@LDU021C22],\ [@LDU021C24]^Medicines reconciliation and discharge3 (4)^[@LDU021C15],\ [@LDU021C24],\ [@LDU021C29][@LDU021C24][@LDU021C24][@LDU021C15],\ [@LDU021C24],\ [@LDU021C29][@LDU021C24][@LDU021C24]^Dispensing errors3 (4)^[@LDU021C17],\ [@LDU021C22],\ [@LDU021C24][@LDU021C17],\ [@LDU021C22],\ [@LDU021C24][@LDU021C22],\ [@LDU021C24][@LDU021C22][@LDU021C22],\ [@LDU021C24][@LDU021C22][@LDU021C24][@LDU021C22],\ [@LDU021C24]^Administration errors3 (4)^[@LDU021C7],\ [@LDU021C22],\ [@LDU021C24][@LDU021C7],\ [@LDU021C22],\ [@LDU021C24][@LDU021C22],\ [@LDU021C24][@LDU021C22],\ [@LDU021C24][@LDU021C22],\ [@LDU021C24][@LDU021C22][@LDU021C24][@LDU021C22],\ [@LDU021C24]^Medicines management in care homes4 (5)^[@LDU021C8],\ [@LDU021C9],\ [@LDU021C30],\ [@LDU021C31][@LDU021C31][@LDU021C8][@LDU021C9][@LDU021C9],\ [@LDU021C31][@LDU021C9][@LDU021C9],\ [@LDU021C30]^Adherence51 (65)^[@LDU021C13],\ [@LDU021C32]--[@LDU021C50]^Epilepsy^[@LDU021C51]^\
Depression^[@LDU021C52]--[@LDU021C54]^\
HIV^[@LDU021C55]--[@LDU021C58]^\
Cardiovascular^[@LDU021C59]--[@LDU021C68]^\
Transplantation^[@LDU021C69]^\
Schizophrenia^[@LDU021C70]--[@LDU021C75]^\
Osteoporosis^[@LDU021C76]^\
Diabetes^[@LDU021C77]^\
Tuberculosis^[@LDU021C78]^\
Asthma^[@LDU021C79],\ [@LDU021C80]^\
Bipolar disease^[@LDU021C81][@LDU021C34],\ [@LDU021C37],\ [@LDU021C47],\ [@LDU021C57],\ [@LDU021C59],\ [@LDU021C68],\ [@LDU021C70][@LDU021C52],\ [@LDU021C56],\ [@LDU021C62][@LDU021C56][@LDU021C36],\ [@LDU021C46],\ [@LDU021C47],\ [@LDU021C56],\ [@LDU021C68],\ [@LDU021C79][@LDU021C36]--[@LDU021C41],\ [@LDU021C44],\ [@LDU021C46]--[@LDU021C49],\ [@LDU021C51],\ [@LDU021C53]--[@LDU021C55],\ [@LDU021C58]--[@LDU021C69],\ [@LDU021C74]--[@LDU021C80],\ [@LDU021C82][@LDU021C34],\ [@LDU021C35],\ [@LDU021C37]--[@LDU021C39],\ [@LDU021C41],\ [@LDU021C47],\ [@LDU021C48],\ [@LDU021C51],\ [@LDU021C53],\ [@LDU021C56],\ [@LDU021C65],\ [@LDU021C67],\ [@LDU021C70]--[@LDU021C79],\ [@LDU021C82][@LDU021C43]^\
\
\
^[@LDU021C13],\ [@LDU021C32],\ [@LDU021C33],\ [@LDU021C36],\ [@LDU021C37],\ [@LDU021C41],\ [@LDU021C42],\ [@LDU021C45],\ [@LDU021C47],\ [@LDU021C50],\ [@LDU021C56],\ [@LDU021C57],\ [@LDU021C59],\ [@LDU021C62],\ [@LDU021C63],\ [@LDU021C68],\ [@LDU021C70],\ [@LDU021C74],\ [@LDU021C76]^\
\
^[@LDU021C37],\ [@LDU021C41],\ [@LDU021C54],\ [@LDU021C65][@LDU021C36],\ [@LDU021C79]^Monitoring3 (4)^[@LDU021C15],\ [@LDU021C17],\ [@LDU021C83][@LDU021C17],\ [@LDU021C83][@LDU021C15]^Other2 (3)2^[@LDU021C84][@LDU021C85]^Total7845 (58)33 (42)24 (31)8 (10)1 (1)9 (12)46 (59)25 (32)1 (1)19 (24)9 (12)5 (6)[^1]

Table [2](#LDU021TB2){ref-type="table"} summarizes the disease areas by issue of suboptimal use of medicines included in the 29 cost-effectiveness studies. Similarly to the systematic reviews on effectiveness, the majority of the studies (16, 55%) focused on adherence. For example, in Al-Eidan *et al*. patients were counselled by the hospital pharmacist on the importance on the adherence to therapy^[@LDU021C105]^; Desborough *et al*. assessed a pharmacist-led medication review to help patients manage their medicines^[@LDU021C103]^; Schroeder *et al*. evaluated a nurse-led support intervention to increase adherence and reduce blood pressure.^[@LDU021C113]^ Prescription errors were the focus of eight studies (28%), such as Weeks *et al*.\'s quality improvement project to reduce medication errors^[@LDU021C96]^ and Sano *et al.* on standardized chemotherapy order forms to reduce errors in the prescribing of antineoplastic medication.^[@LDU021C91]^ Six studies (21%) addressed more than one issue of suboptimal use of medicines.^[@LDU021C86],[@LDU021C88],[@LDU021C91],[@LDU021C93],[@LDU021C94],[@LDU021C98]^ No study evaluated insufficient prescribing of low-cost generics. There was approximately a 50:50 split on whether studies were specific to a disease area or generic. Table [2](#LDU021TB2){ref-type="table"} also shows the various types of interventions evaluated. The classification of interventions into types followed the rationale used for the classification of interventions in the systematic reviews (see above). Various types of interventions were evaluated. Pharmacist-led interventions were the most frequent (17, 59%), particularly for reducing prescription errors.^[@LDU021C92]--[@LDU021C95],[@LDU021C98]^ Table 2Issue of suboptimal use of medicines and interventions in cost-effectiveness studies (references in superscript numbers)Issue of suboptimal medicines use*N (*%)Disease areaSoftware supportPharmacist -led interventionNurse-led supportMultidisciplinary medicines managementFinancial incentivesAdherence aids, tools, devicesDose simplificationsQuality improvement initiativeAllSpecific conditionsLack of compliance with guidelines2 (7)Cardiovascular^[@LDU021C86],\ [@LDU021C87][@LDU021C87][@LDU021C86]^Inappropriate prescribing (inc. antibiotics)4 (14)^[@LDU021C88]^Antibiotic prescribing^[@LDU021C89],\ [@LDU021C90]^\
Cancer^[@LDU021C91][@LDU021C88],\ [@LDU021C90][@LDU021C89][@LDU021C91]^Prescription errors8 (28)^[@LDU021C92]--[@LDU021C97]^Injectables in paediatrics^[@LDU021C98]^\
Cancer^[@LDU021C91][@LDU021C94],\ [@LDU021C97],\ [@LDU021C98][@LDU021C92]--[@LDU021C95],\ [@LDU021C98][@LDU021C98][@LDU021C91],\ [@LDU021C94],\ [@LDU021C98][@LDU021C96]^Dispensing errors2 (7)^[@LDU021C94]^Injectables in paediatrics^[@LDU021C98][@LDU021C94],\ [@LDU021C98][@LDU021C94],\ [@LDU021C98][@LDU021C98][@LDU021C94],\ [@LDU021C98]^Administration errors2 (7)Injectables in paediatrics^[@LDU021C98]^\
Analgesia^[@LDU021C99][@LDU021C98][@LDU021C98][@LDU021C98][@LDU021C98],\ [@LDU021C99]^Medicines management in care homes1 (3)Psychoactive medication^[@LDU021C100][@LDU021C100]^Adherence16 (55)^[@LDU021C88],\ [@LDU021C93],\ [@LDU021C101]--[@LDU021C104]^Erradiation of H.pilory^[@LDU021C105]^\
HIV^[@LDU021C106]--[@LDU021C108]^\
Cardiovascular^[@LDU021C86],\ [@LDU021C109]--[@LDU021C113][@LDU021C86],\ [@LDU021C88],\ [@LDU021C93],\ [@LDU021C101]--[@LDU021C105],\ [@LDU021C110],\ [@LDU021C112][@LDU021C107],\ [@LDU021C108],\ [@LDU021C113][@LDU021C111][@LDU021C106],\ [@LDU021C109][@LDU021C105][@LDU021C111]^Monitoring1 (3)Anticoagulant monitoring^[@LDU021C114][@LDU021C114]^**Total (%)**-12 (41)17 (59)4 (14)17 (59)4 (14)2 (7)2 (7)5 (17)1 (3)1 (3)

Types of studies {#s3b}
----------------

The evidence around interventions to address suboptimal use of medicines was varied but all types of issues were assessed with randomized controlled trials (RCTs). The number of RCTs included in the systematic reviews varied from 1 to 81 (median = 10). Five systematic reviews (6%) included no RCTs.^[@LDU021C7],[@LDU021C26]--[@LDU021C28],[@LDU021C49]^ Most cost-effectiveness studies (19, 66%) conducted a within-trial cost-effectiveness analysis using data from a single RCT^[@LDU021C86],[@LDU021C87],[@LDU021C100],[@LDU021C102],[@LDU021C105],[@LDU021C106],[@LDU021C112],[@LDU021C113]^ or a non-randomized study, such as before and after^[@LDU021C90],[@LDU021C96],[@LDU021C99],[@LDU021C101],[@LDU021C103],[@LDU021C114]^ or cohort studies.^[@LDU021C88],[@LDU021C89],[@LDU021C91],[@LDU021C95],[@LDU021C110]^ Eleven cost-effectiveness studies (38%) used a model, either based on a single study,^[@LDU021C92],[@LDU021C104]^ a review of the literature^[@LDU021C93],[@LDU021C97],[@LDU021C107],[@LDU021C108],[@LDU021C109],[@LDU021C111]^ or from expert evidence elicitation.^[@LDU021C94]^

Outcome measures {#s3c}
----------------

Table [3](#LDU021TB3){ref-type="table"} summarizes the outcome measures used in the studies included in the systematic reviews and in the cost-effectiveness studies. Most studies evaluated the effects of interventions with intermediate outcomes. Intermediate outcomes (e.g. adherence, blood pressure, number of pills taken, error rates) precede and may lead to final outcomes, such as resource use, mortality or quality-adjusted survival. Most systematic reviews report measures of adherence (52, 67%), which is consistent with interventions\' objectives. Adherence was measured in a variety of ways. For example, Bärnighausen *et al*. reports that, of the 26 studies included in their review, 11 used patients\' self-reported adherence, 5 used pill counts, 4 used pharmacy refill rates and 17 used clinical indicators of adherence (e.g. CD4 cell count).^[@LDU021C82]^ Similarly, Al-Jumah *et al*. reports that six of the studies used patients\' self-reported adherence, three used pill counts, two prescription claims and one an electronic pill container.^[@LDU021C52]^ Clinical outcomes measures (24, 31%) and measures of adverse drug events (16, 21%) are also frequent. No study reports QALYs but four (5%) report measures of quality of life. Including final outcome measures such as QALYs can be useful to demonstrate the value of the intervention in improving health. In terms of cost-effectiveness studies, and given the preference for QALYs for decision-making, it is important to distinguish studies that use QALYs as the measure of benefit compared with other measures of quality of life.^[@LDU021C115]^ For the cost-effectiveness studies, clinical outcome measures were the most frequently used (8, 28%), such as blood pressure^[@LDU021C86],[@LDU021C110],[@LDU021C113]^ and rate of thrombotic or haemorrhagic events.^[@LDU021C88],[@LDU021C114]^ QALYs are used in five studies (17%). In De Giorgi *et al*. outcomes were expressed as point reductions in the criticality index for each safety tool; the criticality index was calculated by multiplying the frequency, severity and detection scores obtained by consensus from a panel of two nurses, one neonatologist and three hospital pharmacists.^[@LDU021C98]^ Table 3Types of outcome measures (references in superscript numbers)Issue of suboptimal medicines useType of outcome measureMortalityResource useQuality of lifeQuality-adjusted life yearsAdverse drug eventsMedication errorAppropriatenessAdherenceClinical outcomePatients\' Satisfaction or knowledgeDiscrepancies in recordsAdherence to guidelinesSRESRESRESRESRESRESRESRESRESRESRESREPoor compliance with guidelines^[@LDU021C9][@LDU021C9][@LDU021C10],\ [@LDU021C11][@LDU021C11][@LDU021C7]--[@LDU021C9],\ [@LDU021C12][@LDU021C86][@LDU021C10][@LDU021C9],\ [@LDU021C11][@LDU021C86],\ [@LDU021C87][@LDU021C7][@LDU021C7],\ [@LDU021C12]^Inappropriate prescribing (inc. antibiotics)^[@LDU021C14],\ [@LDU021C15],\ [@LDU021C17][@LDU021C90][@LDU021C14],\ [@LDU021C15][@LDU021C10],\ [@LDU021C11],\ [@LDU021C15],\ [@LDU021C16],\ [@LDU021C19][@LDU021C90][@LDU021C11],\ [@LDU021C16]--[@LDU021C18][@LDU021C91][@LDU021C14],\ [@LDU021C16],\ [@LDU021C17][@LDU021C89],\ [@LDU021C90][@LDU021C10],\ [@LDU021C13],\ [@LDU021C15][@LDU021C88][@LDU021C11],\ [@LDU021C19][@LDU021C88],\ [@LDU021C89][@LDU021C15]^Prescription errors^[@LDU021C26],\ [@LDU021C27][@LDU021C23],\ [@LDU021C25][@LDU021C94][@LDU021C11],\ [@LDU021C20],\ [@LDU021C21],\ [@LDU021C23]--[@LDU021C28][@LDU021C93],\ [@LDU021C95],\ [@LDU021C97][@LDU021C11],\ [@LDU021C20],\ [@LDU021C22]--[@LDU021C27][@LDU021C91],\ [@LDU021C92],\ [@LDU021C95],\ [@LDU021C96][@LDU021C98][@LDU021C11],\ [@LDU021C21]^Medicines reconciliation and discharge^[@LDU021C15][@LDU021C15][@LDU021C15],\ [@LDU021C24][@LDU021C24][@LDU021C15][@LDU021C15][@LDU021C29]^Dispensing errors^[@LDU021C17][@LDU021C94][@LDU021C24][@LDU021C17],\ [@LDU021C22],\ [@LDU021C24][@LDU021C17][@LDU021C98]^Administration errors^[@LDU021C99][@LDU021C24][@LDU021C22],\ [@LDU021C24][@LDU021C7][@LDU021C98][@LDU021C7][@LDU021C7]^Medicines management in care homes^[@LDU021C9],\ [@LDU021C30][@LDU021C9],\ [@LDU021C30][@LDU021C30][@LDU021C30],\ [@LDU021C31][@LDU021C8],\ [@LDU021C9],\ [@LDU021C30][@LDU021C100][@LDU021C9],\ [@LDU021C30][@LDU021C30]^Adherence^[@LDU021C34],\ [@LDU021C47],\ [@LDU021C49],\ [@LDU021C50],\ [@LDU021C67],\ [@LDU021C71],\ [@LDU021C80][@LDU021C102],\ [@LDU021C112][@LDU021C46],\ [@LDU021C47],\ [@LDU021C50][@LDU021C102],\ [@LDU021C103][@LDU021C107]--[@LDU021C109],\ [@LDU021C111][@LDU021C93][@LDU021C49][@LDU021C86][@LDU021C13],\ [@LDU021C32],\ [@LDU021C33],\ [@LDU021C35]--[@LDU021C41],\ [@LDU021C43]--[@LDU021C80],\ [@LDU021C82][@LDU021C88],\ [@LDU021C103],\ [@LDU021C104],\ [@LDU021C106],\ [@LDU021C112],\ [@LDU021C113][@LDU021C32]--[@LDU021C34],\ [@LDU021C39],\ [@LDU021C40],\ [@LDU021C42],\ [@LDU021C46],\ [@LDU021C47],\ [@LDU021C50],\ [@LDU021C52],\ [@LDU021C57],\ [@LDU021C62],\ [@LDU021C65],\ [@LDU021C66],\ [@LDU021C77],\ [@LDU021C80],\ [@LDU021C82][@LDU021C86],\ [@LDU021C88],\ [@LDU021C105],\ [@LDU021C110],\ [@LDU021C113][@LDU021C34],\ [@LDU021C49],\ [@LDU021C52][@LDU021C101],\ [@LDU021C102]^Monitoring^[@LDU021C15],\ [@LDU021C17][@LDU021C15],\ [@LDU021C83][@LDU021C15][@LDU021C17][@LDU021C17][@LDU021C15][@LDU021C114][@LDU021C15]^Other^[@LDU021C84],\ [@LDU021C85][@LDU021C84],\ [@LDU021C85][@LDU021C84][@LDU021C84],\ [@LDU021C85][@LDU021C84][@LDU021C84][@LDU021C84][@LDU021C84],\ [@LDU021C85][@LDU021C84]^Total9 (12)1 (3)16 (21)3 (10)4 (5)2 (7)05 (17)16 (21)4 (14)15 (19)4 (149 (12)5 (17)52 (67)6 (21)24 (31)8 (28)5 (6)2(7)3 (4)02 (3)0[^2]

Countries {#s3d}
---------

The literature on effectiveness appears to span a wide range of countries. Of those structured abstracts reporting the country of origin of the primary effectiveness studies (36; 46%), most studies are based in the USA or Canada (33; 42%), followed by continental Europe (22; 28%) and the UK (19; 24%). A similar picture emerges from the cost-effectiveness studies: the majority are based in the USA or Canada (15; 52%), followed by the UK (7; 24%) and continental Europe (5; 17%).

Discussion {#s4}
==========

There is a large amount of evidence on interventions to improve suboptimal use of medicines. The largest body of evidence is on the effectiveness of interventions to improve adherence to medication, particularly in a specific disease area. Suboptimal prescribing is also an issue of considerable research, namely interventions aimed at reducing prescription errors and inappropriate prescribing. Interventions to address other issues around suboptimal use of medicines have been evaluated to a much lesser extent. No systematic reviews or cost-effectiveness studies were found on interventions to increase the prescribing of low-cost generics or in improving record keeping. The lack of evidence on interventions to increase prescribing of low-cost generics may be related to the relatively large proportion of generic penetration in some countries such as the UK and that pharmacists, depending on the country, may be allowed to automatically switch a branded medicine to a generic when dispensing.^[@LDU021C116],[@LDU021C117]^ The literature on cost-effectiveness is much smaller than on effectiveness. Nonetheless, a similar picture emerges: interventions to improve adherence are the focus of the majority of cost-effectiveness studies, followed by interventions to improve prescribing.

Medicines optimization is a growing topic in the policy agenda. The Royal Pharmaceutical Society has recently issued guidance on medicines optimization for pharmacists and pharmacy technicians.^[@LDU021C1]^ This guidance sets out four key principles to be adopted by all professionals involved in medicines use: an understanding of patient\'s experience, evidence-based choice of medicines, safe use of medicines and making medicines optimization part of routine practice. It has been endorsed by NHS England, the Academy of Medical Royal Colleges, the Royal College of General Practitioners, the Royal College of Nursing and the Association of the British Pharmaceutical Industry. In addition, a number of clinical commissioning groups (NHS organizations responsible for the delivery of NHS services in England) have introduced medicines optimization as a tool to achieve better health outcomes and more efficient use of resources. However, and as highlighted by this review, medicines optimization is a wide area with a large number of issues that could be targeted for improvement. Therefore, it is difficult to make definite recommendations on the comparative effectiveness and cost-effectiveness of different interventions in different stages of the medicines pathway. NICE, for example, is developing a guideline to help clarify how to achieve medicines optimization in practice and maximize the benefits obtained from medicines. It will focus on three topics that relate to the all the stages in medicines pathway: reducing medicines-related patient safety incidents, evidence-informed decision-making and professional collaboration. This selection of topics, although well-defined in scope, may prove challenging to cover in one single guideline and some difficult choices may need to be made on which areas to prioritize for systematic review and cost-effectiveness analysis.

The majority of the studies evaluated effectiveness and cost-effectiveness in terms of intermediate outcomes, such as adherence or error rates, in specific diseases. The implication by using these intermediate measures is that patient outcomes are probably affected. However, virtually no studies attempt to link the two, either by empirical measurement or by modelling. This link may be more or less evidence based; for example, restricting the use of non-steroid anti-inflammatories in people with previous gastro-intestinal bleeding has a strong evidence base, whereas avoiding cardio-selective beta-blockers in people with asthma does not.^[@LDU021C118]^ Within each of these process categories, there is little standardization of definition or measurement, making further comparison between studies especially problematic. In addition, the link between the same intermediate measure and final outcomes may depend on the disease areas considered. For example, poor adherence to anti-retroviral medication has probably greater short-term impact on health compared with poor adherence to cholesterol-lowering therapies. Therefore, an intervention may be cost-effective in one disease but not cost-effective in another, and it is unclear how would it compare overall with other interventions in other disease areas. For these reasons, the current evidence base does not allow for comparisons of interventions across different diseases and affecting different stages of the medicines pathway in terms of their effects on final outcomes. Therefore, it is not possible to draw conclusions on which interventions should be prioritized for investment and future research. Consequently, more research is needed on which intermediate outcomes are preferred in order to achieve some standardization and comparability between studies. In particular, guidance is needed on how intermediate outcomes relate to final outcomes to help establish the effectiveness and cost-effectiveness of interventions affecting different diseases and issues of suboptimal use of medicines.

Decision analytic modelling, informed by evidence synthesis and expert elicitation, has the potential to address these without the risks, high-costs and long-time frame of RCTs. Decision modelling could simulate the medicines pathway in a specific disease and integrate formal evidence, such as from RCTs or previous systematic reviews, complemented with input from experts in the form of expert elicitation to address the evidence gaps.^[@LDU021C119]^ The utility of such a model is 2-fold. First, to evaluate the issues around suboptimal use of medicines with the greatest impact in costs and health. For example, whether the health losses from non-adherence are smaller, larger or equivalent to those from prescribing and dispensing errors. Secondly, to compare the costs and health gains from interventions addressing the different issues and ascertain whether, on balance and given the costs of the interventions, which intervention offers the best value. This information could help inform decisions on which interventions should be prioritized for implementation in the NHS. Finally, the model could indicate the key areas of uncertainty with the greatest impact on costs and health which further research should investigate.

This review has scoped the evidence on effectiveness and cost-effectiveness of interventions to address suboptimal use of medicines. The scoping review was systematic, in terms of the searches, data extraction and presentation of results. It is a valuable resource to researchers starting work in medicines optimization for a number of reasons: (i) provides detailed search strategies on a wide range of issues related to suboptimal use of medicines; (ii) classifies studies by type of issue, disease area, type of intervention and type of outcome measures included and (iii) provides the references of the studies by classification. Therefore, researchers seeking to conduct a review on, for example, interventions to reduce prescription errors, could start by examining the 10 studies referenced in Table [2](#LDU021TB2){ref-type="table"}. Similarly, researchers seeking for parameter inputs for a decision model on, for example, mortality associated with inappropriate prescribing, could start by retrieving the references detailed in Table [3](#LDU021TB3){ref-type="table"}. In addition, this review gives some indication on the research questions most valuable to inform future policies.

This scoping review is affected by some limitations. First, only systematic reviews were included in the review of effectiveness. There are three reasons for this: appropriate because this review aimed to map the existing evidence and highlight evidence gaps, rather than make definitive statements on the effectiveness and cost-effectiveness of specific interventions; efficiency because such a strategy was sufficient to meet these objectives and pragmatic since a review of the entire primary literature or of the grey literature would have been a significant task and impractical within the time available. However, this search strategy risks missing recent peer-reviewed studies not yet included in systematic reviews and the grey literature, such as reports on pilot schemes to improve medicines use. In addition, it may have exaggerated the relative proportion of RCTs since non-experimental designs may be excluded from systematic reviews. Secondly, only three databases were searched for records. These three databases were selected because they hold records of studies that would, in principle, meet our inclusion criteria and therefore limit the number of records found and subsequently excluded. The risk that important evidence on effectiveness and cost-effectiveness of interventions was missed was minimized by discussing the results of the review with experts in the field (see Acknowledgements for their identities). Therefore, although some studies will inevitably have been missed, this review is likely to include the most relevant studies and present a representative picture of the size and nature of evidence base on medicines optimization. A third limitation is that relying on the structured abstracts to extract details on the studies included may have added some inaccuracy to the classification of the types of interventions evaluated. Additionally, it was not possible to ascertain whether interventions were informed by an underpinning theory, as recommended by the Medical Research Council framework for the evaluation of complex interventions.^[@LDU021C120]^ However, detailing the exact nature of the intervention was not a major objective of this review, but rather to provide an indication of which types of interventions have been most evaluated for each type of issue on suboptimal medicines use. For these reasons, and despite its limitations, this review meets the objectives specified.

Conclusion {#s5}
==========

There is a large evidence base on the effectiveness of interventions to improve the suboptimal use of medicines; the cost-effectiveness evidence is much smaller. The evidence base is mostly on interventions for one particular stage of the medicines pathway in terms of their effect on intermediate outcomes. Intermediate outcomes can translate into final health benefits and costs differently, depending on how distant they are from final outcomes and on the strength of this link. Therefore, it is difficult to compare interventions that affect different intermediate outcomes. Evidence on final outcomes, such as mortality or QALYs is limited and typically restricted to cost-effectiveness studies. In addition, a significant proportion of the evidence is specific to certain diseases and its generalizability to others is unclear. For these reasons, it has not been possible to draw conclusions on which issues of suboptimal use of medicines should be prioritized for future research. Nonetheless, some areas for potential research have emerged as potentially valuable for the future and informative for policy decisions. These include methods research on appropriate outcome measures (e.g. for adherence), the relationship between intermediate to final outcomes and how best to compare interventions that affect different stages of the medicines pathway.
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[^1]: Other: any pharmacist intervention to improve patient care^[@LDU021C84]^, any intervention to reduce medication adverse events^[@LDU021C85]^

[^2]: SR--systematic reviews; E--cost-effectivenesss.
